Non Alcoholic Fatty Liver Disease Pipeline and Clinical Trials Review H1 2015 Market Research Report

DALLAS, February 1, 2015 /PRNewswire/ --

RnRMarketResearch.com adds Non Alcoholic Fatty Liver Disease (NAFLD) Global Pipeline and Clinical Trials Review, H1, 2015 research reports to its store. These reports provide an overview of the Non Alcoholic Fatty Liver Disease therapeutic pipeline and clinical trials.

The report "Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015″ provides data on the Non Alcoholic Fatty Liver Disease (NAFLD) clinical trial scenario. Non alcoholic fatty liver disease is a progressive complex of liver disease which starts with fat accumulation in the liver without excessive alcohol utilization. Non alcoholic fatty liver disease can be divided into isolated fatty liver in which there is only accumulation of fat and nonalcoholic steatohepatitis in which there is fat and damage to liver cells. Several risk factors increase the possibility of a person developing NAFLD and it's include diabetes, excess weight and obesity, high levels of fat in the blood and abdominal surgery.

This report provides elemental information and data relating to the clinical trials on Non Alcoholic Fatty Liver Disease (NAFLD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. Companies discussed in this Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015 report include Galmed International Ltd., AstraZeneca PLC, TCM Biotech International Corp, Phenex Pharmaceuticals AG, PharmaKing Co., Ltd., Genextra S.p.a., F. Hoffmann-La Roche Ltd., Barij essence Company, Antipodean Pharmaceuticals, Inc., Abbott Laboratories. Order a copy on "Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015" report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=276883 . (This is a premium report priced at US$2500 for a single user License.)

Scope of Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015 covers: Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each; Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type; Listings of discontinued trials (suspended, withdrawn and terminated).

The report "Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies discussed in this Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2015 report include Conatus Pharmaceuticals Inc., Daewoong Pharmaceutical Co., Ltd., Galmed International Ltd., Kyorin Pharmaceutical Co., Ltd., Metabolic Solutions Development Company, LLC, Novartis AG, Phenex Pharmaceuticals AG, Raptor Pharmaceuticals Corp., TCM Biotech International Corp, Tobira Therapeutics, Inc., Verva Pharmaceuticals Limited, Zafgen Inc. Order a copy on "Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2015" report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269573 . (This is a premium report priced at US$2000 for a single user License.)

Scope of Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2015 covers: a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD); reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Non Alcoholic Fatty Liver Disease (NAFLD) and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; review of the Non Alcoholic Fatty Liver Disease (NAFLD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

Global Markets Direct report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Reasons to Buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
  Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  

Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us: 

RnRMarketResearch.com is a database of syndicated market reports for global and regional industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com